Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type

Medical Oncology

Volumn 31, Issue 10, 2014, Pages 1-8

  Jiang, Li ^a   Li, Pengfei ^a   Wang, Hua ^a   Liu, Jun ^a   Zhang, Xinke ^a   Qiu, Huijuan ^a   Zhang, Bei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Extranodal NK T cell lymphoma; Ki 67; Prognosis

Indexed keywords

ASPARAGINASE; BETA 2 MICROGLOBULIN; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; METHOTREXATE; OXALIPLATIN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR INVASION; BLOOD; CHEMORADIOTHERAPY; LYMPHOMA, EXTRANODAL NK-T-CELL; METABOLISM; MIDDLE AGED; NOSE NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CHEMORADIOTHERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; L-LACTATE DEHYDROGENASE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84919917940     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0218-y     Document Type: Article

References (29)

1. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–8. doi:10.1200/JCO.2005.04.1384.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. doi:10.1200/JCO.2008.16.4558.
3. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.
4. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–34. doi:10.1309/AJCP7YLTQPUSDQ5C.
5. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785–90. doi:10.1182/blood-2005-05-2056.
6. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000;22(4):215–20. doi:10.1046/j.1365-2257.2000.00307.x.
7. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182–90. doi:10.1016/S0360-3016(02)02916-4
8. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–21. doi:10.1182/blood-2003-05-1401.
9. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7. doi:10.1182/blood-2008-10-185256.
10. Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996;14(4):1269–74.
11. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, et al. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res. 2007;27(1A):335–42.
12. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231–7. doi:10.1006/excr.2000.4888.
13. Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001;18(1):15–22. doi:10.1385/MO:18:1:15.
14. He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153. doi:10.1186/1471-2407-14-153.
15. Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007;18(8):1382–7. doi:10.1093/annonc/mdm183.
16. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
17. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009;100(12):2242–8. doi:10.1111/j.1349-7006.2009.01319.x.
18. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.
19. Shipp MA, Harrington DP, Anderson JR. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94. doi:10.1056/NEJM199309303291402.
20. Wang L, Wang Zh, Chen Xq, Li Yj, Wang Kf, Xia Yf et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma. Cancer. 2013;119(2):348–55.
21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
22. Grillo-Lopez AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11(4):399–408.
23. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123(3):513–22.
24. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–22. doi:10.1002/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9.
25. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78–84. doi:10.1182/blood-2002-04-1286.
26. Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study. Ann Hematol. 2004;83(7):414–9. doi:10.1007/s00277-004-0855-x.
27. Szczuraszek K, Mazur G, Jelen M, Dziegiel P, Surowiak P, Zabel M. Prognostic significance of Ki-67 antigen expression in non-Hodgkin’s lymphomas. Anticancer Res. 2008;28(2A):1113–8.
28. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21(5):1032–40. doi:10.1093/annonc/mdp418.
29. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol. 2012;29(3):2183–90. doi:10.1007/s12032-011-0030-x.